Shell Asset Management Co. Lowers Position in DaVita Inc. (NYSE:DVA)

Shell Asset Management Co. reduced its stake in DaVita Inc. (NYSE:DVA) by 41.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,879 shares of the company’s stock after selling 1,999 shares during the quarter. Shell Asset Management Co.’s holdings in DaVita were worth $397,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of DVA. Raymond James & Associates grew its stake in DaVita by 135.2% in the 4th quarter. Raymond James & Associates now owns 34,376 shares of the company’s stock valued at $3,601,000 after purchasing an additional 19,759 shares during the period. Assenagon Asset Management S.A. grew its stake in DaVita by 2,178.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company’s stock valued at $11,379,000 after purchasing an additional 103,856 shares during the period. Ritholtz Wealth Management grew its stake in DaVita by 8.1% in the 4th quarter. Ritholtz Wealth Management now owns 7,675 shares of the company’s stock valued at $804,000 after purchasing an additional 574 shares during the period. Fifth Third Bancorp grew its stake in DaVita by 29.5% in the 4th quarter. Fifth Third Bancorp now owns 4,271 shares of the company’s stock valued at $447,000 after purchasing an additional 973 shares during the period. Finally, Oak Thistle LLC bought a new position in DaVita in the 4th quarter valued at $372,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Down 3.6 %

Shares of NYSE DVA opened at $137.32 on Friday. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $147.93. The business has a 50-day simple moving average of $140.63 and a two-hundred day simple moving average of $131.21. The company has a quick ratio of 1.37, a current ratio of 1.43 and a debt-to-equity ratio of 7.95. The company has a market cap of $12.04 billion, a P/E ratio of 15.60, a P/E/G ratio of 1.09 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The firm had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter last year, the firm posted $1.58 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. Research analysts anticipate that DaVita Inc. will post 9.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Barbara J. Desoer sold 5,030 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $138.81, for a total transaction of $698,214.30. Following the transaction, the director now directly owns 10,954 shares in the company, valued at approximately $1,520,524.74. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 2.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on DVA. Truist Financial upped their price objective on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, May 15th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Barclays increased their price target on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Monday, May 6th. Finally, TD Cowen increased their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus price target of $146.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.